Therapeutic Drug Monitoring

Medical Advocates
HIV Drug Monitoring

ARV Drug Resistance Monitoring
Drug-Specific Studies
Abacavir
Atazanavir
Efavirenz
Indinavir
Lopinavir
Maraviroc
Nelfinavir
Nevirapine
Saquinavir
Tenofovir

HIV Therap. Monitoring Main Main New/Newsworthy Home Page

Last Update: April 16, 2017
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

Abacavir

Journal Papers, Abstracts, and Commentaries

Development and Validation of a Selective and Rapid LC-MS-MS Method
for the Quantification of Abacavir in Human Plasma.
Yadav M, Gupta A, Singhal P, Shrivastav PS.
J Chromatogr Sci. 2010;48(8):654-62.
Abstract

Clinically relevant interpretation of genotype for resistance to abacavir.
Brun-Vezinet F, Descamps D, Ruffault A, et al
AIDS. 2003 Aug 15;17(12):1795-1802
Abstract

Atazanavir

Journal Papers, Abstracts, and Commentaries

Evidence-based Therapeutic Drug Monitoring of Atazanavir
Solas C, Muret P.
Therapie. 2011 May-Jun;66(3):213-9
Abstract

Therapeutic Monitoring and Variability of Atazanavir in HIV-Infected Patients, With and Without
HCV Coinfection, Receiving Boosted or Unboosted Regimens.
Regazzi M, Villani P, Gulminetti R, et al
Ther Drug Monit. 2011 May 4.
Abstract

Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir
Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring.
Slish J, Ma Q, Zingman BS, et al
Ther Drug Monit. 2007 Oct;29(5):560-565.
Abstract

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
Cleijsen RM, van de Ende ME, Kroon FP, et al
J Antimicrob Chemother. 2007 Aug 17;
Abstract

Efavirenz

Journal Papers, Abstracts, and Commentaries

Evidence-based Therapeutic Drug Monitoring for Efavirenz
Solas C, Gagnieu MC.
Therapie. 2011 May-Jun;66(3):197-205.
Abstract

Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals
With Active Substance-Related Disorders.
Ma Q, Zingman BS, Luque AE, et al
Ther Drug Monit. 2011 May 4
Abstract

Efavirenz and Nevirapine in HIV-1 Infection : Is There a Role for Clinical Pharmacokinetic
Monitoring?
Dahri K, Ensom MH.
Clin Pharmacokinet. 2007;46(2):109-32.
Abstract

Efavirenz Plasma Concentrations in HIV-Infected Patients: Inter- and Intraindividual Variability
and Clinical Effects.
Stahle L, Moberg L, Svensson JO, Sonnerborg A.
Ther Drug Monit. 2004 Jun;26(3):267-270.
Abstract

Indinavir

Journal Papers, Abstracts, and Commentaries

Evidence-based Therapeutic Drug Monitoring for Indinavir
Barrail-Tran A, Taburet AM, Poirier JM.
Therapie. 2011 May-Jun;66(3):239-46.
Abstract

Lopinavir

Journal Papers, Abstracts, and Commentaries

Evidence-based Therapeutic Drug Monitoring of lopinavir
Barrail-Tran A, Taburet AM, Poirier JM.
Therapie. 2011 May-Jun;66(3):231-8
Abstract

Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.
Caswell RJ, Phillips D, Chaponda M, et al
Int J STD AIDS. 2011 Jan;22(1):11-4.
Abstract

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
Lambert JS, Else LJ, Jackson V, et al
HIV Med. 2010 Aug 18.
Abstract

Drug monitoring and viral response to Lopinavir/Ritonavir or Saquinavir/Ritonavir
containing regimens in individuals infected with the human immunodeficiency virus type 1.
Falkensammer B, Fasser W, Scherer K, et al Int
J Immunopathol Pharmacol. 2005 January-March;18(1):145-154
Abstract

Simplification of Therapeutic Drug Monitoring for Twice-Daily Regimens of
Lopinavir/Ritonavir for HIV infection.
Alexander CS, Montaner JS, Asselin JJ, et al
Ther Drug Monit. 2004 Oct;26(5):516-523.
Abstract

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside
reverse transcriptase inhibitor.
Solas C, Poizot-Martin I, Drogoul MP, et al
Br J Clin Pharmacol. 2004 Apr;57(4):436-40.
Abstract

Maraviroc

Journal Papers, Abstracts, and Commentaries

FULL-TEXT PDF ARTICLE
Development and application of a simple LC-MS method for the determination of plasma
maraviroc concentrations.
Takahashi M, Hirano A, Okubo N, et al
J Med Invest. 2010;57(3,4):245-250.
Paper

Nelfinavir

Journal Papers, Abstracts, and Commentaries

Limited Sampling Strategy for the Estimation of Systemic Exposure to the Protease
Inhibitor Nelfinavir.
Regazzi MB, Tinelli C, Villani P, et al
Ther Drug Monit. 2005 Oct;27(5):571-575.
Abstract

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naiveHIV-1-infected
individuals.
Burger D, Hugen P, Reiss P, et al.
AIDS. 2003 May 23;17(8):1157-1165.
Abstract

Nevirapine

Journal Papers, Abstracts, and Commentaries

Evidence-based Therapeutic Drug Monitoring for Nevirapine
Muret P, Piedoux S, Solas C, Quaranta S.
Therapie. 2011 May-Jun;66(3):187-95
Abstract

Efavirenz and Nevirapine in HIV-1 Infection : Is There a Role for Clinical Pharmacokinetic
Monitoring?
Dahri K, Ensom MH.
Clin Pharmacokinet. 2007;46(2):109-32.
Abstract

Saquinavir

Journal Papers, Abstracts, and Commentaries

Evidence-based Therapeutic Drug Monitoring for Saquinavir
Muret P, Solas C.
Therapie. 2011 May-Jun;66(3):207-12.
Abstract

Tenofovir

Journal Papers, Abstracts, and Commentaries


	Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring. Barkil ME, Gagnieu MC, Guitton J. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 19; Abstract

HIV Therap. Monitoring Main Main New/Newsworthy Home Page